Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.320.06%
QQQ
740.800.06%
BTC/USD
83967.790.4543%
DIA
513.900.08%
GLD
393.200.08%
TLT
80.550.11%

Dyne Therapeutics Inc (DYN) Stock Price, Quote, News & History

DYNNASDAQ
Trade with Public
Trade with Public
$16.23
-0.91-5.31%
At close: Sep 23, 5:00 PM EST
$16.24
0.010.06%
After Hours: 4:35 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Dyne Therapeutics (DYN) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$17.08
Close
$16.23
Volume / Avg.
2.64M / 2.67M
Day Range
$16.18 - $17.08
52 Wk Range
11.92 - 27.31
Market Cap
$3.03B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
20
Short Interest
14.24%
Days to Cover
13.54

Recent Dyne Therapeutics, Inc. News

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
Vandana Singh

Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
Avi Kapoor

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Avi Kapoor

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
Avi Kapoor

Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-477.82M
Investing Cash Flow (TTM)
-44.17M
Financing Cash Flow (TTM)
713.47M
Free Cash Flow (TTM)
-499.22M
Capital Expenditure (TTM)
-21.40M
Net Change in Cash (TTM)
191.48M

Analyst Trends and Forecast

1
1
May
1
Jun
3
Jul
3
1
Sep
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$2.52B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
4.56
Earnings Yield % (TTM)
-19.02%
Earnings Yield % (FWD)
-18.76%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$3.76

Company Debt

Total Debt
$199.33M
LT Debt
$199.33M
LT Debt Issuance (TTM)
$98.90M
LT Debt Repayment (TTM)
-
Total Cash
$676.11M
Debt to Equity
0.31
Issuance of Debt (TTM)
$98.90M
Repayment of Debt (TTM)
-

Key Statistics

Open
$17.08
Close
$16.23
Volume / Avg.
2.64M / 2.67M
Day Range
$16.18 - $17.08
52 Wk Range
11.92 - 27.31
Market Cap
$3.03B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
20
Short Interest
14.24%
Days to Cover
13.54

About

Sector
Health Care
Industry
Biotechnology
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therape...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Dyne Therapeutics (DYN) stock?

A

You can purchase shares of Dyne Therapeutics (NASDAQ:DYN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Dyne Therapeutics (DYN) competitors?

Q

What is the forecast, or price target, for Dyne Therapeutics (DYN) stock?

A

Dyne Therapeutics has a consensus price target of $38.90.

Q

What is the current price for Dyne Therapeutics (DYN)?

A

The stock price for Dyne Therapeutics (NASDAQ: DYN) is $16.24 last updated September 23, 2026 at 4:35 PM EDT.

Q

Does Dyne Therapeutics (DYN) pay a dividend?

A

There are no upcoming dividends for Dyne Therapeutics.

Q

When is Dyne Therapeutics (NASDAQ:DYN) reporting earnings?

A

Dyne Therapeutics does not have any upcoming earnings scheduled.

Q

Is Dyne Therapeutics (DYN) going to split?

A

There is no upcoming split for Dyne Therapeutics.

Q

What sector and industry does Dyne Therapeutics (DYN) operate in?

A

Dyne Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved